CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 90 target
Drug / intervention
Luspatercept +1 moredrug
Likely dose
Luspatercept 1.0mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07636486
NCT07636486Phase 2Not Yet Recruiting
CompareCT.gov

Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies

Nanfang Hospital, Southern Medical University·interventional·Posted Jun 9, 2026·Updated Jun 9, 2026

In Brief

A Phase 2 clinical trial evaluating Luspatercept and Epoetin for Luspatercept and 3 related conditions. Not yet recruiting, targeting 90 participants across 1 site.

Detailed Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLuspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
CountriesChina
Collaborators--

Timeline

Phase 2Not Yet Recruiting
20272028202920302031
First PostedJun 9, 2026
Enrollment StartJun 15, 2026
Primary CompletionJun 30, 2028
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 22 days agoPrimary completion in 2.0 years

Arms & Interventions

Luspatercept groupexperimental

Luspatercept

Drug: Luspatercept
Epoetin groupactive_comparator

Epoetin

Drug: Epoetin

Interventions

Luspaterceptdrug

Luspatercept is administered 1.0mg/kg subcutaneously every 3 weeks; If the hemoglobin level does not increase after two consecutive administrations, the dose will be adjusted to 1.3mg/kg. If the hemoglobin level returns to the normal range, Luspatercept will be given once before discontinuing the medication.

Epoetindrug

Epoetin is administered 15000 IU subcutaneously every 3 weeks for 24 weeks